Cangene   3Q Revenues: $40.2 million (+46%) 3Q Earnings: $3.8 million (loss of $4.6 million 3Q13) YTD Revenues: $102.6 million (+24%) YTD Earnings: $5.0 million (loss of $12.9 million YTD12) Comments: The increase included an $18.6-million holdback payment from the U.S. government that was triggered by Cangene achieving licensure of botulism antitoxin (BAT). The revenue increase was partially offset by lower HepaGam B sales in the U.S. Also, the prior-year quarter included product and plasma...